$17.96
7.66% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

ADMA Biologics, Inc. Stock price

$19.45
+3.62 22.87% 1M
-0.12 0.61% 6M
+2.30 13.41% YTD
+13.10 206.30% 1Y
+17.42 858.13% 3Y
+16.36 529.45% 5Y
+10.19 110.04% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.78 3.86%
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

Key metrics

Market capitalization $4.62b
Enterprise Value $4.60b
P/E (TTM) P/E ratio 24.03
EV/FCF (TTM) EV/FCF 41.65
EV/Sales (TTM) EV/Sales 10.79
P/S ratio (TTM) P/S ratio 10.84
P/B ratio (TTM) P/B ratio 13.19
Revenue growth (TTM) Revenue growth 65.15%
Revenue (TTM) Revenue $426.45m
EBIT (operating result TTM) EBIT $138.98m
Free Cash Flow (TTM) Free Cash Flow $110.45m
Cash position $103.15m
EPS (TTM) EPS $0.81
P/E forward 27.39
P/S forward 9.33
EV/Sales forward 9.29
Short interest 6.53%
Show more

Is ADMA Biologics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

ADMA Biologics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ADMA Biologics, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a ADMA Biologics, Inc. forecast:

Buy
100%

Financial data from ADMA Biologics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
426 426
65% 65%
100%
- Direct Costs 207 207
22% 22%
49%
219 219
148% 148%
51%
- Selling and Administrative Expenses 70 70
28% 28%
16%
- Research and Development Expense 1.81 1.81
45% 45%
0%
147 147
391% 391%
34%
- Depreciation and Amortization 8.05 8.05
3% 3%
2%
EBIT (Operating Income) EBIT 139 139
542% 542%
33%
Net Profit 198 198
800% 800%
46%

In millions USD.

Don't miss a Thing! We will send you all news about ADMA Biologics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ADMA Biologics, Inc. Stock News

Neutral
Investors Business Daily
about 3 hours ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
Seeking Alpha
14 days ago
ADMA Biologics shows robust revenue growth, driven by its innovative IVIG product, ASCENIV, which targets primary humoral immunodeficiency and includes RSV antibodies. Q4 earnings reveal a 59% year-over-year revenue increase, with strong gross profit margins and minimal R&D expenses, highlighting ADMA's efficient operations. Financial health is solid with $103.147 million in cash and manageable...
Positive
Investors Business Daily
15 days ago
This biopharmaceutical firm specializes in treatments to prevent and treat infectious diseases. The post ADMA Stock Builds A Base As Profits Continue To Soar appeared first on Investor's Business Daily.
More ADMA Biologics, Inc. News

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Head office United States
CEO Adam Grossman
Employees 685
Founded 2004
Website www.admabiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today